Just five days after raising $105 million in a series E financing round, RNA interference therapeutics specialist Sirnaomics Inc. obtained another IND approval from the FDA for its dual-targeting small interfering RNA (siRNA) inhibitor STP-707 to start a basket study in oncology. Sirnaomics’ CEO Patrick Lu told BioWorld in an exclusive interview that an I.V. administration of STP-707 will be tested to tackle solid cancers that may have metastasized into other potential areas or tissue types in the body.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Beigene, Biocytogen, Genfit, Hutchmed, Orum, Sanyou, Strand, Triastek.
PERTH, Australia – Startup Currus Biologics Pty Ltd. has launched with a AU$10 million (US$7.5 million) series A round with the mission of improving the success of CAR T-cell therapies against solid tumors such as breast, ovarian and pancreatic cancers.
PERTH, Australia – Immutep Ltd. announced a AU$60 million (US$45.1 million) capital raise via two tranches to progress two clinical programs of its lead immunotherapy, eftilagimod alpha, to registration studies.
CAR T specialist Carsgen Therapeutics Holdings Ltd.’s shares started trading on the Hong Kong Stock Exchange on June 18, helping the company raise HK$3.1 billion (US$400 million) from an IPO that will allow it to advance its phase II-stage BCMA CAR T therapy candidate, CT-053, in multiple markets.
Multinational antibody specialist Hifibio Therapeutics Inc. closed an oversubscribed $75 million series D financing round to move its anti-TNFR2 antibody HFB-200301 and the anti-OX-40 antibody HFB-301001 to phase I trials by the end of this year.
Inmagene Biopharmaceuticals Co. Ltd. has raised $100 million in a series C financing to move its IL-17 inhibitor to phase II trials in the U.S. and China.
RSS
